StreetInsider.com News Articles

Form 6-K Ascendis Pharma A/S For: Jun 17

Wed, 17 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260617/26660690.html

Form 6-K Ascendis Pharma A/S For: Jun 17

Wed, 17 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260617/26660690.html

Form 6-K Ascendis Pharma A/S For: Jun 17

Wed, 17 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260617/26660690.html

Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND)

Mon, 15 Jun 2026 07:07:17 -0400

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $262.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst commented: "Ascendis unveiled long-term data at the European Congress of Endocrinology (ECE) and at ENDO, the annual Endocrine Society meeting, reinforcing Yorvipath's ability to broadly address hypoparathyroid patients' physiologic needs. Across up to five years in Phase 2 and three-and-a-half years in Phase 3, Yorvi continues to demonstrate durable response rates (82% and 86%, respectively) while maintaining favorable effects on renal function, urinary calcium excretion, bone health, and patient-reported outcomes. Importantly, these findings have remained consistent across datasets and follow-up periods, supporting

Form 6-K Ascendis Pharma A/S For: Jun 15

Mon, 15 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260615/26643714.html

Form 6-K Ascendis Pharma A/S For: Jun 15

Mon, 15 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260615/26643714.html

Form 6-K Ascendis Pharma A/S For: Jun 12

Fri, 12 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260612/26637910.html

Form 6-K Ascendis Pharma A/S For: Jun 12

Fri, 12 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260612/26637910.html

Ascendis reports 5-year TransCon PTH data in hypoparathyroidism patients

Thu, 11 Jun 2026 16:01:16 -0400

Ascendis Pharma A/S (NASDAQ: ASND) announced results from a 5-year Phase 2 trial showing sustained efficacy and safety of TransCon PTH in adults with hypoparathyroidism. The study followed 59 patients through 266 weeks of treatment.

The trial showed 82% of patients met a multi-component endpoint including normal serum calcium levels, independence from active vitamin D, and reduced calcium supplementation. Additionally, 95% of the original patients completed the five-year study period.

Key findings included normalized urine calcium levels within 26 weeks that remained stable through the study duration. Kidney function showed improvement with mean estimated glomerular filtration rate increasing by 9.4 mL/min/1.73 m²

Ascendis reports 5-year TransCon PTH data in hypoparathyroidism patients

Thu, 11 Jun 2026 16:01:16 -0400

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Thu, 11 Jun 2026 16:01:00 -0400

– Multi-organ system and quality-of-life benefits sustained through five years of treatment

– 82% response rate for the multi-component endpoint

– 95% of patients completed five years of treatment

COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the five-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced,

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Thu, 11 Jun 2026 16:01:00 -0400

– Multi-organ system and quality-of-life benefits sustained through five years of treatment

– 82% response rate for the multi-component endpoint

– 95% of patients completed five years of treatment

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Thu, 11 Jun 2026 16:01:00 -0400

– Multi-organ system and quality-of-life benefits sustained through five years of treatment

– 82% response rate for the multi-component endpoint

– 95% of patients completed five years of treatment

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Thu, 11 Jun 2026 16:01:00 -0400

– Multi-organ system and quality-of-life benefits sustained through five years of treatment

– 82% response rate for the multi-component endpoint

– 95% of patients completed five years of treatment

Form 6-K Ascendis Pharma A/S For: Jun 10

Wed, 10 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629943.html

Form 6-K Ascendis Pharma A/S For: Jun 10

Wed, 10 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629943.html

Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND)

Tue, 09 Jun 2026 06:51:34 -0400

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $262.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst commented: "We believe ASND is oversold following a development in the ongoing ITC investigation into Yuviwel initiated by BMRN (OP). Should the recommendation in a recent ITC staff brief ultimately drive the ruling, we view the potential business harm to ASND—which we anticipate would be $600–700M in lost revenue over a three-year period—as hardly justifying the ~$2.5B market cap decline since May 22. We view the ITC staff's recommendation as a worst-case scenario for ASND, and as it excludes import restrictions for

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026